Belite Bio stock maintains Buy rating at H.C. Wainwright on trial progress

Published 03/07/2025, 12:38
Belite Bio stock maintains Buy rating at H.C. Wainwright on trial progress

Investing.com - H.C. Wainwright has reiterated a Buy rating and $100.00 price target on Belite Bio, Inc, ADR (NASDAQ:BLTE), currently trading at $56.81 with a market cap of $1.85 billion, following the completion of enrollment in a key clinical trial. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $50 to $110.

The company announced on July 2 that its Phase 3 PHOENIX trial has successfully enrolled 500 subjects across multiple countries including the U.S., the UK, France, Czech Republic, Switzerland, China, Taiwan, and Australia.

The PHOENIX trial is evaluating tinlarebant for geographic atrophy (GA) in a global, multicenter, randomized, double-masked, and placebo-controlled study, with subjects randomized in a 2:1 ratio to receive either tinlarebant or placebo.

The primary efficacy endpoint measures the slowing of DDAF lesion growth rate from baseline to Month 24 compared to placebo, with an interim analysis planned at the study’s midpoint.

H.C. Wainwright noted that tinlarebant differentiates from other GA treatments as a once-daily oral tablet targeting earlier stage dry AMD (NASDAQ:AMD), with PHOENIX trial participants having relatively smaller lesion sizes compared to those in clinical trials of competing treatments SYFOVRE and IZERVAY.

In other recent news, Belite Bio Inc reported a narrower-than-expected loss for the first quarter of 2025, with earnings per share (EPS) at -$0.27, beating the forecasted -$0.37. This positive earnings surprise reflects the company’s strategic financial management despite increased operational expenses. Belite Bio’s R&D expenses rose to $9.4 million from $6.8 million year-over-year, while G&A expenses increased to $6.1 million from $1.6 million. The company maintains a strong cash position, with $157.4 million in liquidity, which is projected to support its operations for four years.

Additionally, Belite Bio achieved a significant regulatory milestone as the FDA granted Breakthrough Therapy Designation to its drug candidate, Tinlarebant, for the treatment of Stargardt disease. This designation aims to expedite the development of drugs that show substantial improvement over existing therapies. Analyst firms such as Benchmark and Cantor Fitzgerald have maintained their positive outlook on Belite Bio, with Benchmark reiterating a Buy rating and an $80 price target. Cantor Fitzgerald also reaffirmed its Overweight rating, citing confidence in the company’s commercial and manufacturing preparations for its drug PRGN-2012. These developments underscore Belite Bio’s progress in advancing its clinical trials and strategic plans.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.